Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Vical reports interim data from phase II trial of Leuvectin

Sep. 26, 2000

ImmunoGen/SmithKline Beecham open second trial of cancer treatment

Sep. 26, 2000

Inhibition of NK cells by cancer cells from patients with CML prevented by Maxamine

Sep. 26, 2000

Biomira reports update of drug development programs

Sep. 25, 2000

Seattle Genetics initiates phase I trial of SGN-10 combination therapy

Sep. 21, 2000

Maxamine scheduled for December advisory panel review

Sep. 20, 2000

Cel-Sci receives grant for cervical cancer study with Multikine

Sep. 20, 2000

Phase I/II clinical trial demonstrates safety and tolerability of GVAX lung cancer vaccine

Sep. 15, 2000

Novel duocarmycin derivative suitable for use in anticancer immunoconjugates

Sep. 15, 2000

NCI sponsors additional phase II studies of Prostvac VF vaccine

Sep. 13, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...